Evidence map›Paper›PMID 36909715›Full record

ArticleFrontiers in chemistry2023

Qualitative and quantitative studies on two commercial specifications of

Yi Nan, Haizhen Liang, Xu Pang, Wei Zheng, Yuhao Shi, Xiaojuan Chen, Jie Zhang, Juan Song, Baiping Ma

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Drug design, development and therapy · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi NanBeijing Institute of Radiation Medicine, Beijing, China.
Haizhen LiangBeijing Institute of Radiation Medicine, Beijing, China.
Xu PangBeijing Institute of Radiation Medicine, Beijing, China.
Wei ZhengBeijing Institute of Radiation Medicine, Beijing, China.
Yuhao ShiBeijing Institute of Radiation Medicine, Beijing, China.
Xiaojuan ChenBeijing Institute of Radiation Medicine, Beijing, China.
Jie ZhangBeijing Institute of Radiation Medicine, Beijing, China.
Juan SongBeijing Institute of Radiation Medicine, Beijing, China.
Baiping MaBeijing Institute of Radiation Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rhizoma of

Indexed as

commercial specificationPolygonatum odoratumquality controlUHPLC-CADUHPLC-Q-TOF/MS

Identifiers

PMID36909715
PMCPMC9995655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.